Drug Profile
Transferrin-tirapazamine conjugate
Alternative Names: Tirapazamine/transferrin; Transferrin-tirapazamineLatest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Nanjing University
- Developer Nanjing EffecttPharm Drug Development Corporation
- Class Antineoplastics; Drug conjugates; Glycoproteins; Triazines
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Cancer in China (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in China
- 02 Jul 2016 Preclinical trials in Cancer in China (unspecified route)